Published in Hypertension on January 01, 1995
Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes (2008) 1.57
Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest (2002) 1.25
Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm (2011) 0.84
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. J Pharm Pharm Sci (2014) 0.82
An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease. Alzheimers Res Ther (2016) 0.78
Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol (1999) 0.78
Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding. Br J Pharmacol (2016) 0.77
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol (1999) 0.75
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ (2001) 4.66
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 2.71
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Knowledge, attitudes, and practices on hypertension in a country in epidemiological transition. Hypertension (1998) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther (2009) 1.57
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.48
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol (2006) 1.46
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest (2001) 1.41
Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock (2001) 1.41
Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension (1997) 1.41
[Antihypertensive agents used as first line agents: beta-blockers under pressure]. Rev Med Suisse (2006) 1.39
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Vasopeptidase inhibition and angio-oedema. Lancet (2000) 1.27
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Diet acids and alkalis influence calcium retention in bone. Osteoporos Int (2001) 1.24
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.20
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med (2001) 1.19
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest (2001) 1.13
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer (2008) 1.13
Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J (1978) 1.12
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal Biochem (1999) 1.12
Isolated office hypertension: a prehypertensive state? J Hypertens (1996) 1.11
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A (2001) 1.11
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension (2000) 1.11